HIV mucosal vaccine: Nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses

Journal of Immunology

Volumn 170, Issue 1, 2003, Pages 495-502

  Sakaue, Gaku ^a   Hiroi, Takachika ^a   Nakagawa, Yoko ^c   Someya, Kenji ^d   Iwatani, Kohich ^a   Sawa, Yoshiki ^b   Takahashi, Hidemi ^c   Honda, Mitsuo ^d   Kunisawa, Jun ^a   Kiyono, Hiroshi ^a,e,f  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; LIPOSOME; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CELL ISOLATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; FECES; HEMOPHILIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNIZATION; JAPAN; LAMINA PROPRIA; MONONUCLEAR CELL; MOUSE; MOUSE STRAIN; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; SALIVA; SALIVARY GLAND; SPLEEN; TH1 CELL; TH2 CELL; VAGINA; VIRUS STRAIN;

EID: 0037223094     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.1.495     Document Type: Article

References (45)

1. Cohen, O., D. Weissman, and A. S. Fauci. 1999. The immunopathogenesis of HIV infection. In Fundamental Immunology, 4th Ed. W. E. Paul, ed. Lippincott-Raven, Philadelphia, p. 1455.
2. Staats, H. F., S. P., Montgomery, and T. J. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13:945.
3. Imaoka, K., C. J. Miller, M. Kubota, M. B. McChesney. B. Lohman, M. Yamamoto, K. Fujihashi, K. Someya, M. Honda, J. R. McGhee, and H. Kiyono. 1998. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J. Immunol. 161:5952.
4. Childers, N. K., K. L. Miller, G. Tong, J. C. Llarena, T. Greenway, J. T. Ulrich, and S. M. Michaleck. 2000. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun. 68:5509.
5. Kaneda, Y. 1999. Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol. Membr. Biol. 16:119.
6. Saeki, Y., and Y. Kaneda. 1998. Protein-modified liposomes (HVJ-liposome) for the delivery of genes, oligonucleotides, and proteins. In Cell Biology: A Laboratory Handbook. 2nd Ed. J. E. Celis, ed. Academic Press, San Diego, p.123.
7. Kunisawa, J., S. Nakagawa, and T. Mayumi. 2001. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: Application to vaccine development. Adv. Drug Deliv. 52:177.
8. Kunisawa, J., T. Nakanishi, I. Takahashi, A. Okudaira, Y. Tsutsumi, K. Katayama, S. Nakagawa, H. Kiyono, and T. Mayumi. 2001. Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system. J. Immunol. 167:1406.
9. Yamamoto, S., H. Kiyono, M. Yamamoto, M. Imaoka, K. Fujihashi, F. W. Van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267.
10. Hiroi, T., K. Iwatani, H. Iijima, S. Kodama, M. Yanagita, and H. Kiyono. 1998. Nasal immune system: Distinctive Th0 and Th1/Th2 type environments in murine nasal-associated lymphoid tissues and nasal passage, respectively. Eur. J. Immunol. 28:3346.
11. Asanuma, H., Y. Inaba, C. Aizawa, T. Kurata, and S. Tamura. 1995. Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. J. Immunol. Methods 187:41.
12. Mega, J., J. R. McGhee, and H. Kiyono. 1992. Cytokine- and Ig-producing T cells in mucosal effector tissues: Analysis of IL-5- and IFN-γ-producing T cells, T cell receptor expression, and IgA plasma cells from mouse salivary gland-associated tissues. J. Immunol. 148:2030.
13. Jackson, R. J., K. Fujihashi, J. Xu-Amano, H. Kiyono, C. O. Elson, and J. R. McGhee. 1993. Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 61:4272.
14. Hiroi, T., M. Yanagita, N. Ohta, G. Sakaue, and H. Kiyono. 2000. IL-15 and IL-15 receptor selectively regulate differentiation of common mucosal immune system-independent B-1 cells for IgA responses. J. Immunol. 165:4329.
15. Yanagita, M., T. Hiroi, N. Kitagaki, S. Hamada, H. C. Ito, H. Shimauchi, S. Murakami, H. Okada, and H. Kiyono. 1999. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: Fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production. J. Immunol. 162:3559.
16. Takahashi, H., J. Cohen, A. Hosmalin, K. B. Cease, R. Houghten, J. L. Cornette, C. DeLisi, B. Moss, R. N. Germain, and J. A. Berzofsky. 1988. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105.
17. Takahashi, H., R. Houghten, S. D. Putney, D. H. Margulies, B. Moss, R. N. Germain, and J. A. Berzofsky. 1989. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J. Exp. Med. 170:2023.
18. Nakagawa Y., T. Takeshita, J. A. Berzofsky, and H. Takahashi. 2000. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes. Immunology 101:76.
19. Honda, M., K. Matsuo, T. Nakasone, Y. Okamoto, H. Yoshizaki, K. Kitamura, W. Sugiura, K. Watanabe, Y. Fukushima, S. Haga, et al. 1995. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA 92:10693.
20. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J. Y. Xu, E. A Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type I variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538.
21. Steinmer, K. S., C. J. Scandella, P. V. Skiles, and N. L. Haigwood. 1991. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science 254:105.
22. Parr, E. L., and M. B. Parr. 1997. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 71:8109.
23. Buge, S. L., E. Richardson, S. Alipanah, P. Markham, S. Cheng, N. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:8531.
24. Hu, K. F., K. Lovgren-Bengtsson, and B. Morein. 2001. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev. 51:149.
25. Staats, H. F., S. P. Montgomery, and T. J. Palker. 1997. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res. Hum. Retroviruses 13:945.
26. Porgador, A., H. F. Staats, B. Faiola, E. Gilboa, and T. J. Palker. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J. Immunol. 158:834.
27. Mizuguchi, H., T. Nakagawa, S. Toyosawa, M. Nakanishi, S. Imazu, T. Nakanishi, Y. Tsutsumi, S. Nakagawa, T. Hayakawa, N. Ijuhin, and T. Mayumi. 1998. Tumor necrosis factor α-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors. Cancer Res. 58:5725.
28. Nakanishi, M., H. Mizuguchi, K. Ashihara, T. Senda, A. Eguchi, A. Watabe, T. Nakanishi, M. Kondo, T. Nakagawa, A. Masago, et al. 1999. Gene delivery systems using the Sendai virus. Mol. Membr. Biol. 16:123.
29. Nakanishi, T., A. Hayashi, J. Kunisawa, Y. Tsutusumi, K. Tanaka, Y. Y. Ohtani, M. Nakanishi, H. Fujiwara, T. Hamaoka, and T. Mayumi. 2000. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 30:1740.
30. Tashiro, M., N. L. McQueen, and J. T. Seto. 1999. Determinants of organ tropism of Sendai virus. Front. Biosci. 4:D642.
31. Yonemitsu, Y., C. Kitson, S. Ferrari, R. Farley, U. Griesenbach, D. Judd, R. Steel, P. Scheid, J. Zhu, P. K. Jeffery, et al. 2000. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat. Biotechnol. 18:970.
32. Nakanishi, T., J. Kunisawa, A. Hayashi, Y. Tsutsumi, K. Kubo, S. Nakagawa, H. Fujiwara, T. Hamaoka, and T. Mayumi. 1997. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem. Biophys. Res. Commun. 240:793.
33. Gregoriadis, G., B. McCormack, M. Obrenovic, R. Saffie, B. Zadi, and Y. Perrie. 1999. Vaccine entrapment in liposomes. Methods 19:156.
34. Algarte, M., H. Nguyen, C. Heylbroeck. R. Lin, and J. Hiscott. 1999. IκB-mediated inhibition of virus-induced β interferon transcription. J. Virol. 73:2694.
35. Hershberg, R. M., and L. F. Mayer. 2000. Antigen processing and presentation by intestinal epithelial cells: Polarity and complexity. Immunol. Today 21:123.
36. Telega, G. W., D. C. Baumgart, and S. R. Carding. 2000. Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states. Gastroenterology 119:1548.
37. Stevens, T. L., A. Bossie, V. M. Sanders, R. Fernandez-Botran, R. L. Coffman, T. R. Mosmann, and E. S. Vitetta. 1988. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255.
38. Clerici, M., F. T. Hakim, D. J. Venzon, S. Blatt, C. W. Hendrix, T. A. Wynn, and G. M. Shearer. 1993. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J. Clin. Invest. 91:759.
39. Graziosi, C., G. Pantaleo, K. R. Gantt, J. P. Fortin, J. F. Demarest, O. J. Cohen, R. P. Sekaly, and A. S. Fauci. 1994. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248.
40. Maggi, E., M. Mazzetti, A. Ravina, F. Annunziato, M. de Carli, M. P. Piccinni, R. Manetti, M. Carbonari, A. M. Pesce, G. del Prete, et al. 1994. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 265:244.
41. Albert, J., B. Abrahamsson, K. Nagy, E. Aurelius, H. Gaines, G. Nystrom, and E. M. Fenyo. 1990. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107.
42. Rosenberg, Z. F., and A. S. Fauci. 1989. The immunopathogenesis of HIV infection. Adv. Immunol. 47:377.
43. Kawamura, M., T. Naito, M. Ueno, T. Akagi, K. Hiraishi, I. Takai, M. Makino, T. Serizawa, K. Sugimura, M. Akashi, and M. Baba. 2002. Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice. J. Med. Virol. 66:291.
44. VanCott, T. C., R. W. Kaminski, J. R. Mascola, V. S. Kalyanaraman, N. M. Wassef, C. R. Alving, J. T. Ulrich, G. H. Lowell, and D. L. Birx. 1998. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J. Immunol. 160:2000.
45. Mantis, N. J., P. A. Kozlowski, D. W. Mielcarz, W. Weissenhorn, and M. R. Neutra. 2001. Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies. Vaccine 19:3990.